blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2142650

EP2142650 - NOVEL HIV-1 REVERSE TRANSCRIPTASE CODON DELETION AND ITS USE IN THE MANAGEMENT AND TREATMENT OF HIV INFECTIONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.03.2014
Database last updated on 02.09.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): TR		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
Emory University
1599 Clifton Road, NE Fourth Floor, Mail Stop 1599-001-1AZ
Atlanta, GA 30322 / US
[2010/02]
Inventor(s)01 / SCHINAZI, Raymond, F.
2881 Peachtree Road, NE
Unit 2204
Atlanta, Georgia 30305 / US
 [2013/21]
Former [2010/02]01 / SCHINAZI, Raymond, F.
2881 Peachtree Road, NE Unit 2204
Atlanta, Georgia 30305 / US
Representative(s)Leißler-Gerstl, Gabriele, et al
Hoefer & Partner
Patentanwälte mbB
Pilgersheimer Strasse 20
81543 München / DE
[N/P]
Former [2013/21]Leissler-Gerstl, Gabriele, et al
Hoefer & Partner
Patentanwälte
Pilgersheimer Strasse 20
81543 München / DE
Former [2010/02]Leissler-Gerstl, Gabriele, et al
Hoefer & Partner Patentanwälte Pilgersheimer Strasse 20
81543 München / DE
Application number, filing date08742752.210.04.2008
[2010/02]
WO2008US04666
Priority number, dateUS20070922838P10.04.2007         Original published format: US 922838 P
[2010/02]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008124192
Date:16.10.2008
Language:EN
[2008/42]
Type: A2 Application without search report 
No.:EP2142650
Date:13.01.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 16.10.2008 takes the place of the publication of the European patent application.
[2010/02]
Type: B1 Patent specification 
No.:EP2142650
Date:22.05.2013
Language:EN
[2013/21]
Search report(s)International search report - published on:EP18.12.2008
ClassificationIPC:C12N15/54, C12N9/12, C12Q1/70, A61K31/7076
[2010/02]
CPC:
G16B20/50 (EP,US); C12Q1/703 (US); C12N9/1276 (EP,US);
G16B20/20 (EP,US); G16B50/00 (EP,US); G16B20/00 (EP,US);
Y10S435/911 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/02]
Extension statesALNot yet paid
BANot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:NEUE HIV-1-REVERSE-TRANSKRIPTASE-CODON-DELETION UND VERWENDUNG DAVON BEI DER HANDHABUNG UND BEHANDLUNG VON HIV-INFEKTIONEN[2010/02]
English:NOVEL HIV-1 REVERSE TRANSCRIPTASE CODON DELETION AND ITS USE IN THE MANAGEMENT AND TREATMENT OF HIV INFECTIONS[2010/02]
French:NOUVELLE DELETION D'UN CODON DE LA TRANSCRIPTASE INVERSE DE VIH-1 ET SON UTILISATION DANS LA GESTION ET LE TRAITEMENT DES INFECTIONS A VIH[2010/02]
Entry into regional phase10.11.2009National basic fee paid 
10.11.2009Designation fee(s) paid 
10.11.2009Examination fee paid 
Examination procedure10.11.2009Examination requested  [2010/02]
29.12.2009Amendment by applicant (claims and/or description)
08.03.2010Despatch of a communication from the examining division (Time limit: M04)
16.07.2010Reply to a communication from the examining division
09.02.2011Despatch of a communication from the examining division (Time limit: M04)
20.06.2011Reply to a communication from the examining division
13.12.2012Communication of intention to grant the patent
27.03.2013Fee for grant paid
27.03.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.03.2010
Opposition(s)25.02.2014No opposition filed within time limit [2014/18]
Fees paidRenewal fee
30.03.2010Renewal fee patent year 03
12.04.2011Renewal fee patent year 04
28.03.2012Renewal fee patent year 05
12.04.2013Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU10.04.2008
AT22.05.2013
BE22.05.2013
CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
HR22.05.2013
IT22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
MT22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
TR22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
[2016/33]
Former [2016/32]HU10.04.2008
AT22.05.2013
BE22.05.2013
CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
HR22.05.2013
IT22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
MT22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2016/31]AT22.05.2013
BE22.05.2013
CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
HR22.05.2013
IT22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
MT22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2016/16]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
HR22.05.2013
IT22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
MT22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2014/52]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
HR22.05.2013
IT22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2014/14]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
HR22.05.2013
IT22.05.2013
LT22.05.2013
LV22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2014/11]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
HR22.05.2013
IT22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2014/10]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
HR22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2014/09]AT22.05.2013
BE22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
HR22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2014/06]AT22.05.2013
BE22.05.2013
FI22.05.2013
HR22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2014/02]AT22.05.2013
FI22.05.2013
HR22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2013/51]AT22.05.2013
FI22.05.2013
HR22.05.2013
LT22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2013/50]AT22.05.2013
FI22.05.2013
LT22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2013/49]AT22.05.2013
FI22.05.2013
LT22.05.2013
SE22.05.2013
SI22.05.2013
NO22.08.2013
GR23.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2013/48]AT22.05.2013
LT22.05.2013
NO22.08.2013
ES02.09.2013
IS22.09.2013
PT23.09.2013
Former [2013/47]LT22.05.2013
NO22.08.2013
PT23.09.2013
Cited inInternational search[X]WO9307259  (SCLEROSEFORENINGEN THE DANISH [DK]) [X] 31-34* page 58 *;
 [X]  - GARCÍA-LERMA J G ET AL, "Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.", JOURNAL OF VIROLOGY OCT 2000, (200010), vol. 74, no. 20, ISSN 0022-538X, pages 9339 - 9346, XP002497088 [X] 1,2,5-7,11-20,35,37,38 * page 9343; figure 3 *

DOI:   http://dx.doi.org/10.1128/JVI.74.20.9339-9346.2000
 [X]  - SCHMIT JEAN-CLAUDE ET AL, "Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries", AIDS (LONDON), (19981022), vol. 12, no. 15, ISSN 0269-9370, pages 2005 - 2015, XP002497089 [X] 1,2,5-7,11-20,35,37,38 * page 2014, paragraph LART; table 2 *

DOI:   http://dx.doi.org/10.1097/00002030-199815000-00012
 [X]  - ZHANG ZHIJUN ET AL, "Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY AUG 2006, (200608), vol. 50, no. 8, ISSN 0066-4804, pages 2772 - 2781, XP002497090 [X] 1,2,5-7,11-16,18-20,35,37,38 * figure 3; table 4 *

DOI:   http://dx.doi.org/10.1128/AAC.00127-06
 [DX]  - SCHINAZI ET AL, "Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses", ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, (20060901), vol. 71, no. 2-3, ISSN 0166-3542, pages 322 - 334, XP005605096 [DX] 23-30,39-42 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.antiviral.2006.03.012
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.